Physician profile
Jon M Rawson
NPI 1124116694
$2,109.29
in general payments reported to CMS, 2019-2025
23 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $63.34 · 2021: $188 · 2022: $432 · 2023: $677 · 2024: $256 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Education: $32.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.68 |
| Education | $32.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.83 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $288.32 | 2023-2025 | Myfembree, Gemtesa |
| Channel Medsystems, INC. | $202.00 | 2022-2023 | |
| Pfizer INC. | $182.14 | 2022-2024 | |
| Myovant Sciences INC. | $140.01 | 2021-2022 | |
| Radius Health, INC. | $133.91 | 2023-2025 | Tymlos |
| Novo Nordisk INC | $90.19 | 2019-2023 | Wegovy |
| Renovia INC | $89.20 | 2019 | |
| Aspira Women'S Health INC | $70.65 | 2022-2023 | Ova1 |
| Astellas Pharma US INC | $62.54 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $61.49 | 2021-2022 | |
| Evofem Biosciences, INC. | $54.39 | 2022-2023 | Phexxi |
| Therapeuticsmd, INC. | $53.24 | 2019 | |
| Avion Pharmaceuticals | $50.03 | 2020-2022 | |
| Millicent US INC | $47.25 | 2024 | Intrarosa, Femring |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $46.15 | 2019-2023 | Slynd |
| Almatica Pharma LLC | $38.74 | 2025 | Teriparatide |
| Roche Diagnostics Corporation | $31.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.66 | 2019 | |
| Smith+Nephew, INC. | $21.43 | 2019 | |
| Amgen INC. | $20.17 | 2022 | |
| Galderma Laboratories, L.P. | $12.75 | 2023 | |
| Abbott Laboratories | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.